BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19383851)

  • 1. Thymidylate synthase gene variations: predictive and prognostic markers.
    Lurje G; Manegold PC; Ning Y; Pohl A; Zhang W; Lenz HJ
    Mol Cancer Ther; 2009 May; 8(5):1000-7. PubMed ID: 19383851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil.
    Vignoli M; Nobili S; Napoli C; Putignano AL; Morganti M; Papi L; Valanzano R; Cianchi F; Tonelli F; Mazzei T; Mini E; Genuardi M
    Pharmacol Res; 2011 Sep; 64(3):242-8. PubMed ID: 21536130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase pharmacogenetics in colorectal cancer.
    Marsh S; McLeod HL
    Clin Colorectal Cancer; 2001 Nov; 1(3):175-8; discussion 179-81. PubMed ID: 12450432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J
    Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
    Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
    J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase levels: prognostic, predictive, or both?
    Allegra C
    J Clin Oncol; 2002 Apr; 20(7):1711-3. PubMed ID: 11919223
    [No Abstract]   [Full Text] [Related]  

  • 12. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
    Iacopetta B; Grieu F; Joseph D; Elsaleh H
    Br J Cancer; 2001 Sep; 85(6):827-30. PubMed ID: 11556832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
    Etienne MC; Chazal M; Laurent-Puig P; Magné N; Rosty C; Formento JL; Francoual M; Formento P; Renée N; Chamorey E; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
    J Clin Oncol; 2002 Jun; 20(12):2832-43. PubMed ID: 12065560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells.
    Wakasa K; Kawabata R; Nakao S; Hattori H; Taguchi K; Uchida J; Yamanaka T; Maehara Y; Fukushima M; Oda S
    PLoS One; 2015; 10(4):e0123076. PubMed ID: 25881233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients.
    Gajjar KK; Vora HH; Kobawala TP; Trivedi TI; Ghosh NR
    Int J Biol Markers; 2018 May; 33(2):180-188. PubMed ID: 29799355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
    Aschele C; Debernardis D; Casazza S; Antonelli G; Tunesi G; Baldo C; Lionetto R; Maley F; Sobrero A
    J Clin Oncol; 1999 Jun; 17(6):1760-70. PubMed ID: 10561213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
    Marcuello E; Altés A; del Rio E; César A; Menoyo A; Baiget M
    Int J Cancer; 2004 Dec; 112(5):733-7. PubMed ID: 15386371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
    Salgado J; Zabalegui N; Gil C; Monreal I; Rodríguez J; García-Foncillas J
    Oncol Rep; 2007 Feb; 17(2):325-8. PubMed ID: 17203168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
    J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review.
    Formentini A; Henne-Bruns D; Kornmann M
    Langenbecks Arch Surg; 2004 Oct; 389(5):405-13. PubMed ID: 15309542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.